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expression positively correlated with Ki-67 expression (R0
0.28; p00.017) in SCC and in AK (R00.49; p00.018).
Various clinico-pathological variables, e.g. morphology,
size of lesions and the depth of neoplastic infiltration were
not associated to MT-expression in both SCC and AK. The
grade of histological differentiation of SCC correlated
Metallothioneins (MT I-IV), small cysteine-rich, metal-
binding proteins, have been described in number of organs,
including the skin [1, 2]. High levels of MT-I and II, the
most widely expressed isoforms, are found in liver, kidneys
and skin, MT-III is predominantly expressed in brain, while
MT-IV has been identified in squamous epithelia of alimen-
tary tract [3–5]. In stratified squamous epithelia MT I and II
were expressed in the basal layer, whereas MT IV was
discovered in the differentiating spinous layer [5].
The main function of MT is their contribution in zinc and
copper homeostasis in cells and tissues. These metallic ions,
being the part of proteins and enzymes (e.g. zinc-dependent
transcription factors or p53 protein), are crucial for proper
cell metabolism and differentiation [2, 6]. Although, MT
serve as antioxidants and protect cells’ structures against
free radicals and toxic influence of heavy metal ions (Cd,
Pb, Ni, Hg) [7, 8], they also have proliferative, antiapoptotic
and angiogenic potential, what explains their role in onco-
genesis and tumor progression [2, 9–11]. MT overexpres-
sion was revealed in variety of human tumors. In many of
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Abstract Metallothioneins (MT) are low-molecular weight
proteins implicated in heavy metal detoxification, zinc and
cooper homeostasis and cell protection against free radicals.
In variety of cancers MT-overexpression was shown, but
there are just a few studies on the role of MT in skin
carcinogenesis. Current study was undertaken to evaluate
MT and Ki-67 expression in pre-cancerous skin lesions as
well as in fully developed skin cancers. 73 squamous cell
carcinomas (SCC), 23 actinic keratoses (AK) and 20 normal
skin samples were included in the study. In obtained paraffin
sections immunohistochemical reactions were performed.
MT-expression in SCC (mean 2.89±1.83) was significantly
higher than in AK (mean 1.69±1.26)(p00.006) and higher
than in normal skin (mean 2±0.79) (p00.0075). The MT-
positively with Ki-67 antigen (p<0.001) and did not corre-
late with MT-expression (p00.06). Ki-67 expression was
higher in SCC and in AK than in healthy skin (p00,003).
In SCC and in AK expression of Ki-67 antigen correlated
positively with MT-expression (respectively p00.017 and
p00.018). MT may serve as a good markers of proliferation
in SCC and AK. MT-overexpression in SCC may suggest a
potential role of MT in skin carcinogenesis.
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Introduction
them a positive correlation between MT overexpression and
aggressive clinical behaviour as well as poorer prognosis
has been found (e.g. for carcinomas of urinary and digestive
tract, breast cancers, lung carcinomas, squamous cell carci-
nomas of oral cavity and larynx as well as malignant mel-
anoma) [1, 12–21]. Some researchers [15, 17, 18] suggested
that less differentiated, anaplastic tumor cells were linked to
higher MT expression, indicating for MT as a potential and
important prognostic factor. Moreover, it was also proved
that the overexpression of MT in tumor cells was responsi-
ble for the development of resistance to anticancer drugs and
radiotherapy [9, 22].
Excessive exposure to ultraviolet radiation (UV) plays
the main role in etiopathogenesis of actinic keratosis (AK)
and squamous cell carcinoma (SCC) [23, 24]. UV causes
increase in reactive oxidative species (ROS) leading to DNA
damage [25]. Due to high level of free radicals, keratinocytes
enhance synthesis of endogenous antioxidants, including MT.
The role and behaviour of MT in skin carcnogenesis still
remain unclear. It should be kept in mind, that AK being a
part of a multi-step carcinogenesis process represents an early
stage in a continuum that leads from carcinoma in situ to
invasive SCC [26–28]. Therefore, the current study was un-
dertaken to evaluate MT expression in SCC as well as in AK.
The aim of the study was also to estimate the eventual relation-
ships between MT expression and the expression of Ki-67
antigen as well as some clinical parameters, including the type
of the tumor.
Materials and Methods
The material consisted of 96 fair-skin biopsies obtained from
73 patients with SCC (mean age of 73.6±14.2 years) and 23
subjects suffering from AK (mean age of 71.4±11.2 years).
The mean duration of the disease was assessed as 23.0±
42.4 months for SCC (range, 1–240 months) and 27.6±
17.7 months for AK (range, 6–84 months). The character-
istics of the studied group is given in the Tables 1. Twenty
samples of clinically unchanged, but sun-exposed skin, tak-
en from healthy volunteers (mean age of 57.3±18.5 years)
during plastic surgery procedures, served as a control. The
study was approved by the Ethics Committee of Wroclaw
Medical University (protocol number-KB 609/2007).
Tissue samples were immersed in 10 % buffered formalin
and embedded in paraffin blocks. Alternate sections were
stained with hematoxylin and eosin and used for further
histological analysis. Two of us, with experience in dermato-
pathology, reviewed all the specimens independently (AZ and
GSM). The histological grade of malignancy in SCC samples
was determined using the Broders' classification based on the
degree of differentiation and keratinization of tumor cells [29].
Moreover, for each tumor the degree of keratinization, nuclear
polimorphism, the invasion level after Clark [30], density and
depth of lymphocytes infiltration were evaluated and graded
as well (Table 2). The samples of AK were devided in 3
groups taking under consideration the histological features
(1 bowenoid, 8 hypertrophic and 14 of atrophic types).
Immunochemistry
Immunohistochemistry was carried out with the monoclonal
antibody E9 (code M0639), which binds specifically MT-I
and MT-II, using a 1:100 dilution for MT and the monoclo-
nal antibody MIB-1 (code M7240) diluted 1:50 for Ki-67
antigen (Dako, Denmark). Four-micrometer-thick tissue
sections were deparaffinized by xylene bath followed by
bath with 100 %, 96 % and 70 % ethanol for 5 min. Slides
were then pretreated by heating citrate buffer in a steamer
and then cooled for 15 min. To block endogenous peroxi-
dase acitivity 3 % H2O2 was added. Next the slides were
rinsed in PBS for 5 min. Afterwards the primary antibody
was added and slides were incubated 18 h at 4°C and
washed in 3 changes of PBS. The sections were then incu-
bated with biotinylated anti-mouse immunoglobulin for
20 min, washed again in 3 changes of PBS before being
incubated with streptavidin–peroxidase complex for 20 min.
The slides were visualized with diaminobenzidine chromo-
gen (DAB) for 5 min. Finally they were placed into distilled
water, stained with hematoxylin and closed with coverslips.
Table 1 The characteristics of the studied group







Age < 60 years 8 11 4 17
60–80 years 43 59 15 66
> 80 years 22 30 4 17
Gender women 29 40 18 78
men 44 60 5 22
Size < 2 cm 46 63 19 83
2–5 cm 23 31,5 4 17
> 5 cm 4 5,5 0 0
Localization Face 39 53 14 61
Lip 13 18 2 9
Ear 12 16 1 9
Scalp 2 3 0 0
Trunk 0 0 1 4
Upper limb 2 3 0 0
Lower limb 5 7 5 22
Morphology Hyperkeratotic 50 68 15 65
Exulcerans 22 30 - -
Vegetans 1 2 - -
Erythematous - - 8 35
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Slides were assessed in magnification of 100x and 200x
and digitally imaged. For the evaluation of the MT expres-
sion semiquantitative Remmele scale was used (Table 3)
[31]. The method takes into account both the intensity
of the color reaction and the percentage of positive cells
in each lesion. The final score (IRS) represents the prod-
uct of these 2 values, ranging from 0 to 12 points: no
reaction 0 pts., weak reaction 1–2 pts., moderate reaction
3–4 pts., intense reaction 6–12 pts. Expression of Ki-67
was also evaluated semiquantitatively by percent of immu-
nopositive cells including the following intervals: 0 % (0
pts.), 1-10 % (1 pts.), 11–25 %, (2 pts.), 26–50 % (3 pts.)
and above 50 % (4 pts.). The localization and distribution
of staining within the normal skin, in AK and SCC has
been studied as well.
Statistical Analysis
All data were analyzed statistically with Statistica® 7.1 soft-
ware (Statsoft, Cracow, Poland). Student’st-test for indepen-
dent variables, Mann–Whitney U test, univariate analysis of
variance with post hoc test and χ2 test were used where
appropriate. Correlations between parameters were mea-
sured with Spearman’s rank correlation test. Results
with p-values less than 0.05 were treated as statistically
significant.
Results
All the healthy skin sections, 21 cases out of AKs (92 %) and
69 cases out of SCCs (95 %) showed MT-immunoreactivity.
Significant differences were observed in localization of MT-
positive cells in normal skin, in AK and in SCC (p<0,01).
In healthy skin MT-expression was revealed in epidermal
basal layer, hair matrix cells and outer hair root sheath,
some cells of sebaceous and eccrine glands. In AK, MT-
positive cells were found mostly in basal and parabasal
layers of atypical epidermis (83 % AK). In well-
differentiated SCCs (Broders 1–2) expression of MT was
found in the periphery of tumor nest (61 % of cases), while
in poorly differentiated SCCs (Broders 3–4) MT-positive
cells were dispersed throughout the entire tumors (67.5 %
cases) (Fig. 1a-d).
The MT expression in SCC was significantly higher than
for AK (p00.006) and higher than in normal skin (p00.07);
no differences in MT-expression between AK and normal
skin were found (p00.81) (Fig. 2.)
Ki-67 antigen was detected in 18 cases out of normal
skin (90 %) and in all samples of SCC and AK. With
regard to its immunostaging, the Ki-67 antigen was sig-
nificantly higher expressed in SCC and in AK (with no
difference between SCC and AK) than in healthy skin
(p00.0025) (Fig. 2).
Table 2 The histological
parameters of evaluated SCC Histological parameters Number of patients
with SCC
%
Broders G1 (>75 % of keratinized cells) 14 19
G2 (50–75 % of keratinized cells) 19 26
G3 (25–50 % of keratinized cells) 25 34




I- invasion into the epidermis 0 0
II- invasion into the papillary dermis 1 1
III- invasion to the junction of the papillary and
reticular dermis
4 5
IV- invasion into the reticular dermis 29 40
V- invasion into the subcutaneous fat 39 54
Density of inflammatory
infiltration around SCC
Mild inflammatory infiltration 19 26
Moderate inflammatory infiltration 40 55














0 No detectable stain
1 <10 % 1 Weak nuclear stain
2 11–50 % 2 Moderate nuclear
stain
3 51–80 % 3 Strong nuclear stain
4 >80 %
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The positive correlation between expression of MT
and the expression of Ki-67 antigen was found in SCC
as well as in AK, however the correlation with an AK
lesions was stronger than with SCC (R00.28; p00.017
and R00.49; p00.018, respectively) (Fig. 3a, b). Such a
phenomenon was absent in normal skin (R0−0.07; p0
0.76). The mentioned above weak correlation between
MT and Ki-67 in SCCs had its reflection in relationships
with Broders’ grading (G) of histological differentiation
of SCC. Contradictory to significant positive correlation
between Ki-67 antigen and the tumour’s G (R00.4; p<
0.001), the MT-expression revealed only weak correla-
tion with tendency to increase in poorly differentiated SCC
(R00.2; p00.06).
Moreover, various clinico-pathological variables, in-
cluding age, gender of patients, localization, morpholo-
gy and size of the lesions, as well as the depth of
neoplastic infiltration and the density and depth of in-
flammatory infiltration did not affect MT-expression in both
SCC and AK.
Fig. 2 The expression of MT





Fig. 1 Normal, unchanged skin
a and AK lesion b—MT-
immunoreactivity expressed
mainly in basal and parabasal
layers of epithelium. Well-
differentiated SCC (G2)
c revealed peripheral MT-
immunostaining, whereas
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Discussion
Only a few studies have been conducted to investigate the
localization and the expression of MT in normal and neo-
plastic keratinocytes. It has been reported that in healthy
skin MT are rather poorly expressed and restricted to basal
and suprabasal layers [5, 32, 33] what was confirmed also in
the present study. The same situation occurred in most AK
lesions—MT expression was observed only in basal and
spinous layers. In well-differentiated SCC the MT were
detected predominantly in the periphery of tumor nest, while
in poorly differentiated squamous cell carcinomas MT pos-
itive cells were dispersed throughout the entire tumor. Sim-
ilar pattern of MT immunostaining has been noticed by
other researches in SCC of skin and tongue [34, 35]. Addi-
tionally, head and neck cancers as well as breast adenocar-
cinomas have shown MT expression in healthy tissues
surrounding the tumors [36, 37]. In the epithelium adjacent
to SCC, the intense MT labeling of suprabasal layer was
detected, what suggests that migrating tumor cells may
induce MT-synthesis in healthy tissue adjacent to the tumor
[34, 36].
It has been found, that epidermal MT-expression is inde-
pendent on clinico-pathological factors like age and gender
of patients, duration of the disease and size, type or locali-
zation of cutaneous SCC. In addition the depth of neoplastic
infiltration as well as density and depth of inflammatory
infiltration around SCC did not influence MT-expression.
Similar observations were made by Borges et al. in non-
melanoma skin cancers (NMSC) [34]. In their study no
significant correlation between MT-expression and size of
tumor, time of the disease or age of patients has been found
either [34].
Various tumor parameters have been studied to predict
the course of SCC. The worse prognosis was linked to:
tumor size (T>2 cm), type of precancerous lesion, localiza-
tion, ulceration, immunosuppression, tumor thickness
(>6 mm), G grading, the depth of tumor infiltration accord-
ing to Clark's scale, histological tumor type and perineural
invasion [30, 38, 39]. Some laboratory based methods were
found to be useful as well. The invasiveness of SCC (and
BCC) was correlated with level of MMP-1 (matrix
metalloproteinase 1) and adhesion molecule CD44v6
[40]. Goldman et al. [38] demonstrated that a combination
of tumor thickness and the expression of cathepsin D may
have a high predictive value. It was also noticed that the
differentiation of SCC was correlated with Ki-67 index [40].
In this study the grade of histological differentiation correlated
positively with Ki-67 antigen in SCC and did not correlate
with MT-expression, however the tendency to an increase of
MT-expression in poorly differentiated SCC was observed.
Perhaps the analysis of a larger group of patients would bring
unequivocal finding and MT-expression would become the
next good marker of SCC malignancy. Similar observation
was made by Muramatsu et al. [37] in oral and pharyngeal
SCC, where MT positive cell index was adequately higher in
poorly differentiated SCC than in well and moderately differ-
entiated SCC.
MTare engaged in cells proliferation and differentiation. In
present study a positive correlation between MT-expression
and Ki-67 expression has been described in AK and in SCC,
which may testify the participation of both proteins in intense
neoplastic proliferation of keratinocytes. The same correlation
was found in colon adenocarcinoma and nosopharyngeal car-
cinoma [41, 42].
Many studies have proved that MT- expression is higher in
cancers in comparison to precancerous lesions. It was ob-
served in laryngeal and nosopharyngeal carcinomas [42, 43]
and may result from higher demand for endogenous zinc and
higher proliferative activity of the neoplastic cells. In the
current reserach the MT- expression was also significantly
Fig. 3 a Positive correlation between MT and Ki-67 antigen expres-
sion in AK. b Positive correlation between MT and Ki-67 antigen
expression in SCC
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higher in SCC than in AK and higher than in normal skin.
Moreover, it has been described by other authors, that a higher
MT-expression in NMSC is associated with tumoral aggres-
siveness. Borges et al. [34] analyzed the differences in MT-
expression in BCC and SCC. In basal cell carcinomas MT-
expression was observed in 18.5 %±21.2 % of tumor cells,
while for squamous cell carcinomas immunostaining indices
were 69.1±14.4 % [34]. Similar conclusion was by Rossen et
al. [44], who have examined MT-expression in different types
of BCC and found that the immunoreactivity was high in
infiltrating/morphea-like BCC, while most nodular BCC,
which have less aggressive clinical behaviour, showed de-
creased or absent of MT-immunostaining [44].
The knowledge of the mechanism responsible for neoplas-
tic transformation of keratinocytes gives an opportunity to
create new diagnostic and therapeutic methods. In our study
we have observed a high expression of Ki-67 antigen in AK
and SCC as well, whileMT-expression was statistically higher
in SCC in comparison to its in AK lesions. A confrontation of
those two values could serve as a helpful diagnostic method
for differentiation of SCC from AK in doubtful cases.
To the best of our knowledge, our study is the first one
comparing the MT- expression in cutaneous SCC and AK.
Moreover, for the first time we showed correlation between
expression of MT and Ki-67 antigen in cutaneous SCC and
AK. In summary, based on our own results, it seems that
MT-overexpression in SCC is an unfavorable factor promot-
ing cutaneous carcinogenesis. This theory requires further
investigations. Perhaps the antioxidative function and anti-
immunosuppressive effect of metallothioneins prevail over
their proliferative and anti-apoptotic properties in healthy
skin, while MT-overexpression in neoplastic epidermal ker-
atinocytes may lead to worsening course of the disease.
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